Mechanisms for the Transition From Physiological to Pathological Cardiac Hypertrophy

Canadian Journal of Physiology and Pharmacology - Canada
doi 10.1139/cjpp-2019-0566
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Canadian Science Publishing

Related search

Fibronectin Contributes to Pathological Cardiac Hypertrophy but Not Physiological Growth

Basic Research in Cardiology
Cardiovascular MedicinePhysiologyCardiology
2013English

Regulation of Thyroid Hormone Receptor Isoforms in Physiological and Pathological Cardiac Hypertrophy

Circulation Research
Cardiovascular MedicinePhysiologyCardiology
2001English

Differential and Conditional Activation of PKC-Isoforms Dictates Cardiac Adaptation During Physiological to Pathological Hypertrophy

PLoS ONE
Multidisciplinary
2014English

Tripartite Motif 32 Prevents Pathological Cardiac Hypertrophy

Clinical Science
Medicine
2016English

Nuclear GAPDH Signaling Mediates Pathological Cardiac Hypertrophy

2019English

Differential Role of G Protein-Coupled Receptor Kinase 5 in Physiological Versus Pathological Cardiac Hypertrophy

Circulation Research
Cardiovascular MedicinePhysiologyCardiology
2015English

The Transcription Factor GATA-6 Regulates Pathological Cardiac Hypertrophy

Circulation Research
Cardiovascular MedicinePhysiologyCardiology
2010English

Gentisic Acid Prevents the Transition From Pressure Overload-Induced Cardiac Hypertrophy to Heart Failure

Scientific Reports
Multidisciplinary
2019English

Tom70 Serves as a Molecular Switch to Determine Pathological Cardiac Hypertrophy

Cell Research
Cell BiologyMolecular Biology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy